John and Harvin Rupp ME, Hamer KE. 1998. Effect of subinhibitory concentrations of vanco- mycin, cefazolin, oﬂoxacin, L-oﬂoxacin and D-oﬂoxacin on adherence to intravascular catheters and bioﬁlm formation by Staphylococcus epidermidis. J Antimicrob Chemother, 41:155–161. Sader HS, Jones RN, Stilwell MG, et al. 2005. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis, 52:181–6. Saginur R, St Denis M, Ferris W, et al. 2006. Multiple combination bac- tericidal testing of staphylococcal bioﬁlms from implant-associated infections. Antimicrob Agents Chemother, 50:55–61. Sahm DF, Marsilio MK, Piazza G. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveil- lance network database-USA. Clin Infect Dis, 29:259–63. Sanches S, Mato R, Lencastre HD, et al. 2000. Patterns of multidrug resistance among methicillin-resistant Hospital Isolates of coagulase- positive and coagulase-negative staphylococci collected in the inter- national multicenter study RESIST in 1997 and 1998. Microb Drug Resist, 6:199–211. Schaberg Dr, Culver DH, Gaynes RP. 1991. Major trends in the microbial etiology of nosocomial infection. Am J Med, 91:S72–5. Schoenbaum SC, Gardner P, Shillito J. 1975. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis, 131:543–52. Sherertz RJ, Boger MS, Collins CA, et al. 2006. Comparative in vitro efﬁca- cies of various catheter lock solutions. Antimicrob Agents Chemother, 50:1865–8. Shinabarger D. 1999. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investg Drugs, 8:1195–202. Silverman JA, Oliver N, Andrew T, et al. 2001. Resistance studies with daptomycin. Antimicrob Agents Chemother, 45:1799–802. Spiliopoulou I, Santos SI, Bartzavali C, et al. 2003. Application of molecu- lar typing methods to characterize nosocomial coagulase-negative staphylococci collected in a Greek hospital during a three-year period (1998–2000). Microb Drug Resist, 9:273–82. Stryjewski ME, Chu VH, O’Riorday WD, et al. 2006. Telavacin veruss standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST study. Antimicrob Agents Chemother, 50:862–7. Sutherland R, Rolinson GN. 1964. Characteristics of methicillin resistant staphylococci. J Bacteriol, 87:887–99. Tristan A, et al. 2006. Biology and pathogenicity of staphylococci other than Staphylococcus aureus and Staphylococcus epidermidis. In: VA Fischetti et al. Gram-Positive Pathogens. 2nd edition. ASM Press. Washington, D.C. p 572–86. von Eiff C, Peters G, Heilmann C. 2002. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis, 2:677–85. Vuong C, Christiane G, Somerville GA, et al. 2003. Quorum-sensing control of bioﬁlm factors in Staphylococcus epidermidis. J Infect Dis, 188:706–18. Widerström M, Monsen T, Karlsson C, et al. 2006. Molecular epidemiology of methicillin-resistant coagulase-negative staphylococci in a Swedish county hospital: evidence of intro- and interhospital clonal spread. J Hosp Infect, 64:177–83. Xu L, Li H, Vuong C, et al. 2006. Role of the luxS quorum-sensing system in bioﬁlm formation and virulence of Staphylococcus epidermidis. Infect Immun, 74:488–96. 1152 Therapeutics and Clinical Risk Management 2007:3(6)